Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GEN-009 |
| Synonyms | |
| Therapy Description |
GEN-009 is a personalized cancer vaccine developed from identified neoantigens in solid tumors in the form of synthetic long peptides (SLPs) (Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 2611-2611). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GEN-009 | GEN009|GEN 009 | GEN-009 is a personalized cancer vaccine developed from identified neoantigens in solid tumors in the form of synthetic long peptides (SLPs) (Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 2611-2611). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03633110 | Phase Ib/II | GEN-009 GEN-009 + Nivolumab | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | Completed | USA | 0 |